Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study ; volume:25 ; number:1 ; day:9 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
BMC pharmacology & toxicology ; 25, Heft 1 (9.8.2024), 1-11, 12.2024

Creator: Lin, Wanlong
Zeng, Yanbin
Weng, Lizhu
Yang, Jianhui
Zhuang, Wei

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40360-024-00770-6

URN: urn:nbn:de:101:1-2410291035168.713307700565

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lin, Wanlong
Zeng, Yanbin
Weng, Lizhu
Yang, Jianhui
Zhuang, Wei
SpringerLink (Online service)

Other Objects (12)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

Related objects

Reset password